期刊
CHILDREN-BASEL
卷 10, 期 11, 页码 -出版社
MDPI
DOI: 10.3390/children10111728
关键词
ovine model; neonates; brain hypoxia-ischemia; clemastine; asphyxia
类别
Clemastine shows promise in treating demyelinating diseases but has no effect on neurodevelopmental outcomes following global ischemic insult.
Originally approved by the U.S. Food and Drug Administration (FDA) for its antihistamine properties, clemastine can also promote white matter integrity and has shown promise in the treatment of demyelinating diseases such as multiple sclerosis. Here, we conducted an in-depth analysis of the feasibility, safety, and neuroprotective efficacy of clemastine administration in near-term lambs (n = 25, 141-143 days) following a global ischemic insult induced via an umbilical cord occlusion (UCO) model. Lambs were randomly assigned to receive clemastine or placebo postnatally, and outcomes were assessed over a six-day period. Clemastine administration was well tolerated. While treated lambs demonstrated improvements in inflammatory scores, their neurodevelopmental outcomes were unchanged.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据